Ladenburg Thalmann Maintains Buy on United Therapeutics, Raises Price Target to $268
Portfolio Pulse from jenniferd'souza@benzinga.com
Ladenburg Thalmann analyst Matthew Kaplan maintains a 'Buy' rating on United Therapeutics (NASDAQ:UTHR) and raises the price target from $256 to $268.
August 04, 2023 | 1:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
United Therapeutics' price target has been raised from $256 to $268 by Ladenburg Thalmann, maintaining a 'Buy' rating.
The raised price target and maintained 'Buy' rating by Ladenburg Thalmann indicates a positive outlook for United Therapeutics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100